After treatment, the staining intensity of VEGF and VEGFR-1 in RBE+M2 group was still significantly higher than that in RBE group, indicating that Lenvatinib could act on the VEGFR target of cholangiocarcinoma and inhibit its kinase activity, thus blocking tumor angiogenesis. This evidence concerns the gene VEGFA and cholangiocarcinoma.